Audit: QRS - Gastrodin for Health & Longevity
Audit conducted on 17/06/2026 05:52 using AI4L / Opus 4.8
Summary
| Items | Count |
|---|---|
| Total | 71 |
| Passed | 67 |
| Failed | 0 |
| N/A | 4 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All content traces to ER (benefits, risks, protocol, monitoring, gates). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “Not established” / “No meaningful timeframe established in humans” mirror ER line 358. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications and cautious framing preserved at ER strength. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Gate items drawn from ER Key Interactions & Contraindications section. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | QRS contains no citations, IDs, expert names, or brands. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions present in the QRS. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Objective, evidence-graded tone consistent with ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert yet plain-language framing throughout. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents evidence, no directives. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No prescriptive advice; footnote disclaimer present. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Informational phrasing used. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person (“you”/”your”) usage found. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms (GABA, etc.) avoided in body; plain wording used. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Compact lists, cells, and tiers. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed no direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing aimed at proactive, risk-aware adults. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Protocol detail (titration, monitoring) assumes this audience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not general-population framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Brain-longevity speculative framing reflects this audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging”. Proper names that contain “anti-aging” are quoted verbatim. | 🟢 | No “anti-aging” usage; title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language. Direct quotes from sources are exempt. | 🟢 | “oral”, “injection”, “blood pressure” used; no colloquialisms. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card/section headings (“Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”); Gate headings (“Contraindications”, “Key Interactions”); Tier labels (“High”, “Medium”, “Low”, “Speculative”); Monitoring table headers (“Marker”, “Target”, “Why”). | 🟢 | All fixed headings/labels present verbatim. |
| 3.2 | All “…” from the [qrs_template] are present in the QRS. | 🟢 | All template var spans present, including hidden ones. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Hidden placeholder spans (time_3, *_high) left intact. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. | 🟢 | No empty-state mismatches; absent tiers hidden, not phrased. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol/marker labels match ER wording. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Labels preserved from ER. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji indicators in QRS. |
| 4.5 | The QRS is designed to render on one A4 page. Any section with more content than fits is condensed by the LLM, not extended onto a second page. | 🟢 | Content condensed into single-page budget. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Metadata comment is first element after doctype. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. | 🟢 | YAML delimited by — pair (lines 3 and 13). |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element. | 🟢 | Enclosed in HTML comment; not rendered. |
| 5.4 | All frontmatter values are trimmed: no leading/trailing whitespace, no surrounding quotes unless the value requires YAML quoting. | 🟢 | Values trimmed; only duration quoted (contains colon). |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]”. | 🟢 | er_filename: gastrodin_2026-0617-0437_Opus_ER.md |
| 5.6 | Version of the QRS.md file used is stated as “qrs_prompt_version: [Version of QRS.md]”. | 🟢 | qrs_prompt_version: 26.5.18 matches QRS.md. |
| 5.7 | Creation date/time is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]”. | 🟢 | qrs_creation_date: 2026-0617-0437 |
| 5.8 | The nickname of the AI is stated as “qrs_creator_ai_nickname: […]”. | 🟢 | qrs_creator_ai_nickname: Opus |
| 5.9 | The nickname is a single word model name without version. | 🟢 | “Opus” — single word. |
| 5.10 | The full name of the AI is stated as “qrs_creator_ai_fullname: […]”. | 🟢 | qrs_creator_ai_fullname: Opus 4.8 |
| 5.11 | The full name consists of the nickname plus the model version number and no additional qualifier. | 🟢 | “Opus 4.8” — nickname + version. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename]”. | 🟢 | qrs_filename: gastrodin_2026-0617-0437_Opus_QRS.html |
| 5.13 | All frontmatter values are trimmed: no leading/trailing whitespace, no surrounding quotes unless required. | 🟢 | Confirmed clean and consistent. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet”. HTML-entity-encoded as needed. | 🟢 | “Gastrodin for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded. | 🟢 | “Gastrodin for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]. | 🟢 | 06/17/2026 from 2026-0617. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname]. | 🟢 | “Opus 4.8”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only date and model; no extras. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section. |
🟢 | Condenses ER Conclusion (lines 420-422). |
| 7.2 | [at_a_glance] is no longer than 60 words. | 🟢 | 52 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each claim maps to ER Conclusion passages. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead. | 🟢 | “add-on”, “nerve signaling”, “inflammation” — plain. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values). | 🟢 | No trial citations. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results. | 🟢 | No numeric effect sizes. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section. |
🟢 | Drawn from ER line 287. |
| 8.2 | [stop_items] represent the Contraindications from the ER. | 🟢 | Pregnancy, allergy, bleeding/surgery, hypotension. |
| 8.3 | Individual [stop_items] are formatted as <li></li>. | 🟢 | Each item is an <li>. |
| 8.4 | Items are as concise as possible. No trailing explanations, elaborations, rationale, attributions, citations, study details, or content after a dash. | 🟢 | Concise; trailing rationale stripped. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved, kept concise. | 🟢 | “within 1–2 weeks”, “(symptomatic low blood pressure)” preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>”), normalize to a plain comma-separated list. | 🟢 | No ranking notation present; N/A condition not triggered, handled cleanly. |
| 8.7 | If no [stop_items] are present the section is left empty. | N/A | stop_items are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section. |
🟢 | Drawn from ER lines 273-285. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any already listed as Contraindications. | 🟢 | Sedatives, antihypertensives, anticoagulants, OTC, GABAergic/BP supplements, betahistine; no overlap with contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li>. | 🟢 | Each item is an <li>. |
| 9.4 | Items are as concise as possible. No trailing explanations, elaborations, rationale, attributions, citations, study details, or content after a dash. | 🟢 | Severity/consequence/mitigation clauses stripped. |
| 9.5 | Parenthetical qualifiers — example drug lists, time windows, severity classes, thresholds, clinical staging — ARE preserved, kept concise. | 🟢 | Example drug lists in parens preserved. |
| 9.6 | When the ER uses ranking notation inside parens, normalize to a plain comma-separated list. | 🟢 | No ranking notation; lists are comma-separated. |
| 9.7 | If no [caution_items] are present the section is left empty. | N/A | caution_items are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section. |
🟢 | Dose, frequency, timing from ER Therapeutic Protocol. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section. |
🟢 | Dose, dosing frequency, best time of day. |
| 10.3 | If less than three distinct actionable implementation aspects are mentioned, unused sets are left empty and made invisible. | N/A | Three distinct actionable aspects exist. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All three action cells populated from ER. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER. | 🟢 | ER provides two distinct aspects (headache/dizziness, brain protection); both used, third hidden per 11.3. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit. | 🟢 | Headache/dizziness (Medium) before brain protection (Speculative). |
| 11.3 | If less than three distinct time-to-effect aspects are mentioned, unused sets are left empty and made invisible. | 🟢 | time_3 hidden via display:none. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | Both used sets populated from ER line 358. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel. | N/A | ER provides time-to-effect information. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section. |
🟢 | Tiers mirror ER Expected Benefits. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]. | 🟢 | All four spans present. |
| 12.3 | Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, or mechanistic explanations. | 🟢 | Bare benefit names only. |
| 12.4 | Parenthetical content — effect sizes, sample notes, mechanistic hints, example studies — is stripped, NOT preserved. | 🟢 | “(Adjunct)” stripped from blood-pressure item. |
| 12.5 | If no items of a sub-section are present the respective SPAN is set to “display=none”, not filled with empty-state phrasing. | 🟢 | benefits_high hidden (no High benefits in ER). |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section. |
🟢 | Tiers mirror ER Potential Risks. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]. | 🟢 | All four spans present. |
| 13.3 | Items are as concise as possible. No explanations, elaborations, effect sizes, qualifiers, attributions, citations, study details, or mechanistic explanations. | 🟢 | Bare risk names only. |
| 13.4 | Parenthetical content — frequencies, severity grades, sample notes, mechanistic hints, example studies — is stripped, NOT preserved. | 🟢 | “(Injectable Form)” and “⚠️ Conflicted” stripped. |
| 13.5 | If no items of a sub-section are present the respective SPAN is set to “display=none”, not filled with empty-state phrasing. | 🟢 | risks_high hidden (no High risks in ER). |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section. |
🟢 | Marker table drawn from ER lines 388-392. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed. |
🟢 | BP, RHR, ALT/AST, CBC, glucose/HbA1c all present. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER. It is not left with placeholder text or empty. | 🟢 | Cadence from ER lines 384-392 populated. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section. |
🟢 | Drawn from ER qualitative markers (lines 396-400). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed. |
🟢 | All five qualitative markers present verbatim. |
Issues 17/06/2026 05:52
Pass rate 100.00%. No issues found.
Issues 17/06/2026 05:46
- 12.3 / 12.4 — Benefit qualifier not stripped: benefits_low (line 528) carries the qualifier “as an adjunct” derived from the ER heading “Blood Pressure Lowering (Adjunct)”; the parenthetical/qualifier should be stripped, leaving “Blood pressure lowering”.
- 13.4 — Parenthetical not stripped: risks_low (line 578) preserves the parenthetical “(injectable form)” on “injection-site and hypersensitivity reactions (injectable form)”; it should be stripped.
Fixes 17/06/2026 05:46
- 12.3 / 12.4 — Benefit qualifier stripped: Removed the “as an adjunct” qualifier from benefits_low so it reads “Blood pressure lowering” instead of “Blood pressure lowering as an adjunct”.
- 13.4 — Parenthetical stripped: Removed the “(injectable form)” parenthetical from risks_low so it reads “injection-site and hypersensitivity reactions”.